Roche gets EMA recommendation for Ocrevus; Anthem now covers Sarepta's exon-skipping Duchenne MD drug
→ The EMA’s Committee for Medicinal Products for Human Use has given a glowing recommendation for Roche’s multiple sclerosis drug Ocrevus (ocrelizumab), paving the way …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
